Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Apr 20;42(12):1415-1425.
doi: 10.1200/JCO.22.02835. Epub 2024 Jan 23.

Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3

Petros Grivas  1 , Damien Pouessel  2 , Chandler H Park  3 , Philippe Barthelemy  4 , Manojkumar Bupathi  5 , Daniel P Petrylak  6 , Neeraj Agarwal  7 , Sumati Gupta  7 , Aude Fléchon  8 , Chethan Ramamurthy  9 , Nancy B Davis  10 , Alejandro Recio-Boiles  11 , Cora N Sternberg  12 , Astha Bhatia  13 , Cabilia Pichardo  13 , Mitch Sierecki  13 , Julia Tonelli  13 , Huafeng Zhou  13 , Scott T Tagawa  12 , Yohann Loriot  14
Affiliations
Clinical Trial

Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3

Petros Grivas et al. J Clin Oncol. .

Abstract

Purpose: Pembrolizumab is standard therapy for patients with metastatic urothelial cancer (mUC) who progress after first-line platinum-based chemotherapy; however, only approximately 21% of patients respond. Sacituzumab govitecan (SG) is a trophoblast cell surface antigen-2-directed antibody-drug conjugate with US Food and Drug Administration-accelerated approval to treat patients with locally advanced or mUC who previously received platinum-based chemotherapy and a checkpoint inhibitor (CPI). Here, we report the primary analysis of TROPHY-U-01 cohort 3.

Methods: TROPHY-U-01 (ClinicalTrials.gov identifier: NCT03547973) is a multicohort, open-label phase II study. Patients were CPI-naïve and had mUC progression after platinum-based chemotherapy in the metastatic setting or ≤12 months in the (neo)adjuvant setting. Patients received 10 mg/kg of SG once on days 1 and 8 and 200 mg of pembrolizumab once on day 1 of 21-day cycles. The primary end point was objective response rate (ORR) per central review. Secondary end points included clinical benefit rate (CBR), duration of response (DOR) and progression-free survival (PFS) per central review, and safety.

Results: Cohort 3 included 41 patients (median age 67 years; 83% male; 78% visceral metastases [29% liver]). With a median follow-up of 14.8 months, the ORR was 41% (95% CI, 26.3 to 57.9; 20% complete response rate), CBR was 46% (95% CI, 30.7 to 62.6), median DOR was 11.1 months (95% CI, 4.8 to not estimable [NE]), and median PFS was 5.3 months (95% CI, 3.4 to 10.2). The median overall survival was 12.7 months (range, 10.7-NE). Grade ≥3 treatment-related adverse events occurred in 61% of patients; most common were neutropenia (37%), leukopenia (20%), and diarrhea (20%).

Conclusion: SG plus pembrolizumab demonstrated a high response rate with an overall manageable toxicity profile in patients with mUC who progressed after platinum-based chemotherapy. No new safety signals were detected. These data support further evaluation of SG plus CPI in mUC.

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Figures

FIG 1.
FIG 1.
Flow diagram. CPI, checkpoint inhibitor; IV, intravenous; mUC, metastatic urothelial cancer.
FIG 2.
FIG 2.
Kaplan-Meier analysis of (A) DOR, (B) PFS, and (C) OS. DOR, duration of response; NE, not estimable; OS, overall survival; PFS, progression-free survival.
FIG 3.
FIG 3.
Tumor responses per central review. (A) Waterfall plot showing best percentage change from baseline in the sum of the diameters of the target lesions in 39 patients (excludes two patients who were missing percentage change from baseline). The dashed line indicates threshold for partial response, according to RECIST v1.1. Target lesions were reduced in 72% of patients (28 of 38) with at least one postbaseline target lesion measurement. (B) Spider plot of tumor response by week. (C) Swimmer plot of response and duration. aPatients who achieved a complete response without a 100% reduction relative to the assessment at baseline had a lymph node as the target lesion. PD, progressive disease.
FIG A1.
FIG A1.
ORR in key prespecified subgroups per central review: forest plot showing ORR in different subgroups. Horizontal line represents CI. aAll patients had two or fewer therapies and two or fewer chemotherapies. ECOG PS, Eastern Cooperative Oncology Group performance status; NA, not available; ORR, objective response rate.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Saginala K, Barsouk A, Aluru JS, et al. Epidemiology of bladder cancer. Med Sci. 2020;8:15. - PMC - PubMed
    1. Powles T, Bellmunt J, Comperat E, et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:244–258. - PubMed
    1. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer V.3.2022. https://NCCN.org.
    1. Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383:1218–1230. - PubMed
    1. Powles T, Park SH, Voog E, et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial. J Clin Oncol. 2022;40 suppl 6; abstr 487. - PMC - PubMed

Publication types

MeSH terms

Associated data